SecuritySYBX / Synlogic, Inc. (60470J103)
IndustryPharmaceutical Preparations
Common Shares Outstanding16,285,271 shares (as of 2017-09-30)
Total Insiders48
Total Directors15
Total Officers12

Stock Insider Trading (from SEC Form 4)

Synlogic, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

SYBX / Synlogic, Inc. insiders include BARRIS PETER J, AKKARAJU SRINIVAS, Miller Paul Francis, Barbosa Miguel, Gutierrez-Ramos Jose-Carlos, Nisen Perry, Jones Elaine V, Mathers Edward T, Atlas Venture Fund IX, L.P., and BASKETT FOREST, Mehra Anand, New Enterprise Associates 14, L.P., Irvin Jon, Sofinnova Management VIII, L.L.C., SIEGALL CLAY B, Alleva Lawrence M, Khuong Chau Quang, ORBIMED ADVISORS LLC, Brennan Aoife, ISALY SAMUEL D Shegog Todd, SANDELL SCOTT D, POWELL MICHAEL, Fuhrman Alan, Lammers Paul, DeYoung Casi, HEALY JAMES, KERINS PATRICK J, BARRETT M JAMES, Leschly Nick, KOLLURI KRISHNA KITTU, Shea Richard P, PFIZER INC, NEA Partners 14, L.P., O'Neill Vincent, Weller Harry R, Viswanathan Ravi, MOTT DAVID M, Sofinnova Venture Partners VIII, L.P., Kim Sinil, Barrett Peter, Florence Anthony A. Jr., NEA 14 GP, LTD, Winkler Matthew, Gengos Andrew, Sonsini Peter W., OrbiMed Capital GP VI LLC, Greenleaf Peter, .

Insider Roster

Insider Dir Off 10% Shares Owned
Gutierrez-Ramos Jose-Carlos See Remarks, Director
X X
Shegog Todd See Remarks
X
Brennan Aoife Chief Medical Officer
X
Gengos Andrew Chief Operating Officer
X
Miller Paul Francis Chief Scientific Officer
X
POWELL MICHAEL Director
X 574,972
Khuong Chau Quang Director
X 2,029,996
ORBIMED ADVISORS LLC Director
OrbiMed Capital GP VI LLC Director
X 2,029,996
Viswanathan Ravi 10% Owner
X 4,228,940
Sonsini Peter W. 10% Owner
X 4,228,940
SANDELL SCOTT D 10% Owner
X 4,228,940
MOTT DAVID M 10% Owner
X 4,228,940
KERINS PATRICK J 10% Owner
X 4,228,940
Florence Anthony A. Jr. 10% Owner
X 4,228,940
BASKETT FOREST 10% Owner
X 4,228,940
BARRIS PETER J 10% Owner
X 4,228,940
BARRETT M JAMES 10% Owner
X 4,228,940
New Enterprise Associates 14, L.P. 10% Owner
NEA 14 GP, LTD 10% Owner
NEA Partners 14, L.P. 10% Owner
X 4,228,940
Mathers Edward T Director
X
Barrett Peter Director
X
Shea Richard P Director
X
Leschly Nick Director
X
Atlas Venture Fund IX, L.P. 10% Owner
X 5,303,926
Irvin Jon Vice President, Finance
X
Nisen Perry Director
X
Winkler Matthew Director
X
Alleva Lawrence M Director
X
SIEGALL CLAY B Director
X
Greenleaf Peter Director
X
O'Neill Vincent Chief Medical Officer
X
DeYoung Casi Chief Business Officer
X
Fuhrman Alan Chief Financial Officer
X
Lammers Paul President & CEO, Director
X X
PFIZER INC 10% Owner
X
Sofinnova Venture Partners VIII, L.P. 10% Owner
Sofinnova Management VIII, L.L.C. 10% Owner
HEALY JAMES 10% Owner
AKKARAJU SRINIVAS 10% Owner
Mehra Anand 10% Owner
X
KOLLURI KRISHNA KITTU 10% Owner
X
Weller Harry R 10% Owner
X
Jones Elaine V Director
X
Barbosa Miguel Chief Scientific Officer
X
Kim Sinil Chief Medical Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-01-26 4 ORBIMED ADVISORS LLC See Footnotes A I 9.75 715,000 2,029,996
2018-01-26 4 Khuong Chau Quang See Footnotes A I 9.75 715,000 2,029,996
2018-01-26 4 POWELL MICHAEL A I 9.75 150,000 574,972
2018-01-26 4 New Enterprise Associates 14, L.P. A D 9.75 410,000 4,228,940
2018-01-26 4 BARRETT M JAMES See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 BARRIS PETER J See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 BASKETT FOREST See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 Florence Anthony A. Jr. See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 KERINS PATRICK J See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 MOTT DAVID M See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 SANDELL SCOTT D See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 Sonsini Peter W. See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 Viswanathan Ravi See Note 1 A I 9.75 410,000 4,228,940
2017-08-28 4 Sonsini Peter W. See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 Viswanathan Ravi See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 BARRETT M JAMES See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 BARRIS PETER J See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 BASKETT FOREST See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 Florence Anthony A. Jr. See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 KERINS PATRICK J See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 MOTT DAVID M See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 SANDELL SCOTT D See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 New Enterprise Associates 14, L.P. A D 3,394,439 3,818,940
2016-12-01 4 Irvin Jon S D 1.4343 280 7,625 10,937
2016-11-11 4 Irvin Jon S D 1.45 -150 7,905 11,462
2016-11-01 4 Irvin Jon S D 1.2839 -280 8,055 10,342
2016-10-11 4 Irvin Jon S D 1.825 -150 8,335 15,211
2016-10-03 4 Irvin Jon S D 1.9254 -250 8,485 16,337
2015-10-06 4 PFIZER INC J D 7.0000 235,855 2,489,364
2015-10-06 4 PFIZER INC P D 7.0000 714,285 2,253,509 15,774,563
2015-10-05 4 PFIZER INC C D 1,539,224 1,539,224
2015-10-06 4 Weller Harry R See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 Weller Harry R See Note 2 J I 31,650 2,114,375
2015-10-06 4 Weller Harry R See Note 2 J I 257,516 1,499,166
2015-10-05 4 Weller Harry R See Note 2 C I 583,559 2,082,725
2015-10-05 4 Weller Harry R See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 Viswanathan Ravi See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 Viswanathan Ravi See Note 2 J I 31,650 2,114,375
2015-10-06 4 Viswanathan Ravi See Note 2 J I 257,516 1,499,166
2015-10-05 4 Viswanathan Ravi See Note 2 C I 583,559 2,082,725
2015-10-05 4 Viswanathan Ravi See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 KOLLURI KRISHNA KITTU See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 KOLLURI KRISHNA KITTU See Note 2 J I 31,650 2,114,375
2015-10-06 4 KOLLURI KRISHNA KITTU See Note 2 J I 257,516 1,499,166
2015-10-05 4 KOLLURI KRISHNA KITTU See Note 2 C I 583,559 2,082,725
2015-10-05 4 KOLLURI KRISHNA KITTU See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 New Enterprise Associates 14, L.P. P D 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 New Enterprise Associates 14, L.P. J D 31,650 2,114,375
2015-10-06 4 New Enterprise Associates 14, L.P. J D 257,516 1,499,166
2015-10-05 4 New Enterprise Associates 14, L.P. C D 583,559 2,082,725
2015-10-05 4 New Enterprise Associates 14, L.P. C D 1,241,650 1,241,650
2015-10-06 4 Florence Anthony A. Jr. See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 Florence Anthony A. Jr. See Note 2 J I 31,650 2,114,375
2015-10-06 4 Florence Anthony A. Jr. See Note 2 J I 257,516 1,499,166
2015-10-05 4 Florence Anthony A. Jr. See Note 2 C I 583,559 2,082,725
2015-10-05 4 Florence Anthony A. Jr. See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 BASKETT FOREST See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 BASKETT FOREST See Note 2 J I 31,650 2,114,375
2015-10-06 4 BASKETT FOREST See Note 2 J I 257,516 1,499,166
2015-10-05 4 BASKETT FOREST See Note 2 C I 583,559 2,082,725
2015-10-05 4 BASKETT FOREST See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 BARRIS PETER J See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 BARRIS PETER J See Note 2 J I 31,650 2,114,375
2015-10-06 4 BARRIS PETER J See Note 2 J I 257,516 1,499,166
2015-10-05 4 BARRIS PETER J See Note 2 C I 583,559 2,082,725
2015-10-05 4 BARRIS PETER J See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 Alleva Lawrence M J I 207 4,025
2015-10-05 4 Alleva Lawrence M C I 3,818 3,818
2015-10-06 4 Winkler Matthew J I 8,408 51,034
2015-10-06 4 Winkler Matthew J I 8,408 51,034
2015-10-06 4 Winkler Matthew J I 8,408 51,034
2015-10-06 4 Winkler Matthew J D 62,582 649,174
2015-10-05 4 Winkler Matthew C I 40,281 42,626
2015-10-05 4 Winkler Matthew C I 2,345 2,345
2015-10-05 4 Winkler Matthew C I 40,281 42,626
2015-10-05 4 Winkler Matthew C I 2,345 2,345
2015-10-05 4 Winkler Matthew C I 40,281 42,626
2015-10-05 4 Winkler Matthew C I 2,345 2,345
2015-10-05 4 Winkler Matthew C D 187,277 586,592
2015-10-05 4 Winkler Matthew C D 235,899 399,315
2015-10-05 4 Winkler Matthew C D 28,458 163,416
2015-10-05 4 Winkler Matthew C D 134,958 134,958
2015-10-06 4 Sofinnova Venture Partners VIII, L.P. P D 7 857,142 2,974,811 20,823,677
2015-10-06 4 Sofinnova Venture Partners VIII, L.P. J D 289,841 2,117,669
2015-10-05 4 Sofinnova Venture Partners VIII, L.P. C D 583,559 1,827,828
2015-10-05 4 Sofinnova Venture Partners VIII, L.P. C D 1,244,269 1,244,269
2015-10-06 4 SANDELL SCOTT D See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 SANDELL SCOTT D See Note 2 J I 31,650 2,114,375
2015-10-06 4 SANDELL SCOTT D See Note 2 J I 257,516 1,499,166
2015-10-05 4 SANDELL SCOTT D See Note 2 C I 583,559 2,082,725
2015-10-05 4 SANDELL SCOTT D See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 KERINS PATRICK J See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 KERINS PATRICK J See Note 2 J I 31,650 2,114,375
2015-10-06 4 KERINS PATRICK J See Note 2 J I 257,516 1,499,166
2015-10-05 4 KERINS PATRICK J See Note 2 C I 583,559 2,082,725
2015-10-05 4 KERINS PATRICK J See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 MOTT DAVID M See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 MOTT DAVID M See Note 2 J I 31,650 2,114,375
2015-10-06 4 MOTT DAVID M See Note 2 J I 257,516 1,499,166
2015-10-05 4 MOTT DAVID M See Note 2 C I 583,559 2,082,725
2015-10-05 4 MOTT DAVID M See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 BARRETT M JAMES See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 BARRETT M JAMES See Note 2 J I 31,650 2,114,375
2015-10-06 4 BARRETT M JAMES See Note 2 J I 257,516 1,499,166
2015-10-05 4 BARRETT M JAMES See Note 2 C I 583,559 2,082,725
2015-10-05 4 BARRETT M JAMES See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 POWELL MICHAEL P I 7.00 857,142 2,974,811 20,823,677
2015-10-06 4 POWELL MICHAEL J I 289,841 2,117,669
2015-10-05 4 POWELL MICHAEL C I 583,559 1,827,828
2015-10-05 4 POWELL MICHAEL C I 1,244,269 1,244,269
2015-10-06 4 Sonsini Peter W. See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 Sonsini Peter W. See Note 2 J I 31,650 2,114,375
2015-10-06 4 Sonsini Peter W. See Note 2 J I 257,516 1,499,166
2015-10-05 4 Sonsini Peter W. See Note 2 C I 583,559 2,082,725
2015-10-05 4 Sonsini Peter W. See Note 2 C I 1,241,650 1,241,650
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...